Home › Non-Small Cell Lung Cancer › Illinois
Non-Small Cell Lung Cancer clinical trials in Illinois
94 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago61 studies
- Cicero24 studies
- Evanston22 studies
- Peoria21 studies
- Waukegan16 studies
- Naperville16 studies
- Decatur14 studies
- Springfield13 studies
- Arlington Heights12 studies
- Joliet12 studies
- North Peoria11 studies
- Aurora11 studies
- Champaign11 studies
- Bloomington11 studies
- Galesburg11 studies
- Danville8 studies
- Charleston8 studies
- Elgin6 studies
- Carbondale5 studies
- Rockford4 studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Rush-Copley Medical Center, Aurora
- Advocate Good Shepherd Hospital, Barrington
- Illinois CancerCare-Bloomington, Bloomington
- and 42 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- The University of Chicago Medical Center ( Site 0118), Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- University of Illinois Cancer Center, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06472245A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- and 19 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- OSF Saint Francis Medical Center, Peoria
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07365319Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Illinois Cancer Care ( Site 7000), Peoria
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- and 23 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07388524A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Duly Healthcare ( Site 0158), Lisle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07554339Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Northwestern University, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- Northwestern Medicine Cancer Center Delnor, Geneva
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- University of Chicago Medical Center, Chicago
- Endeavor Health, Evanston
- Illinois Cancer Care, Peoria
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0423, Urbana
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Hope And Healing Cancer Services /ID# 276223, Hinsdale
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- University of Illinois Cancer Center, Chicago
- Center for Care and Discovery, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Illinois Cancer Specialists, Arlington Heights
- Illinois CancerCare- Bloomington, Bloomington
- Illinois Cancer Specialists, Chicago
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- North Shore University Health System ( Site 4014), Evanston
- Accellacare of Duly ( Site 4005), Lisle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Illinois CancerCare - Bloomington, Bloomington
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- University of Illinois Chicago, Chicago
- Illinois Cancer Specialists, Niles
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Hope and Healing Clinical Research, Hinsdale
- Hope and Healing Clinical Research, New Lenox
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07489066This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Endeavor Health, Elmhurst
- Hope and Healing Cancer Services, Hinsdale
- Advocate Medical Group - Libertyville Oncology, Libertyville
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- University of Illinois at Chicago, Chicago
- Cancer Care Specialists of Central Illinois, Decatur
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07154290A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Chicago
- Research Site, Decatur
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- City of Hope, Chicago, Chicago
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- Cancer Care Specialists of Illinois (CCSI), O'Fallon
- Carle Health, Urbana
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Illinois CancerCare-Bloomington, Bloomington
- and 33 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Affiliated Oncologists, LLC, Chicago Ridge
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Hinsdale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- OSF Health Care, Peoria
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07140016Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Chicago
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Northwest Oncology & Hematology, Elk Grove Village
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07028489A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- University of Illinois Hospital and Health Sciences System /ID# 275345, Chicago
- Illinois Cancer Specialists /ID# 274678, Niles
- Springfield Clinic - First /ID# 272576, Springfield
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06568939Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Rush University Medical Center, Chicago
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080An External Control Arm Study in Non-Small Cell Lung Cancer
- Northwest Oncology and Hematology, Barrington
- Northwest Oncology and Hematology, Elk Grove
- Northwest Oncology and Hematology, Hoffman Estates
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174388A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Illinois Cancer Specialists, Arlington Heights
- University of Illinois at Chicago, Chicago
- Springfield Clinic Main Campus, Springfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06875310Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Chicago
- Research Site, Decatur
- Research Site, Hinsdale
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.